LLY Jan 2025 220.000 put
| Previous Close | 1.2500 |
| Open | 1.3400 |
| Bid | 0.8600 |
| Ask | 1.9500 |
| Strike | 220.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 1.2500 - 1.3400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 16 |
ReutersUS judge overturns Eli Lilly's $176.5 million loss in Teva patent case
Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy. U.S. District Judge Allison Burroughs said in a post-trial ruling that the Teva patents covering the use of antibodies to inhibit headache-causing peptides were invalid. "The Court does not reach this decision nor overturn a jury verdict lightly," Burroughs said.
Motley Fool2 Magnificent Dividend Stocks to Buy Right Now
If you're looking for dividend stocks that can boost your portfolio returns, you should consider high-quality companies that can pay consistent and growing dividends. Two dividend stocks that stand out as strong buys right now are Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). Here's why these two top-notch dividend stocks are still worth buying, even though they sport premium valuations.
ZacksFDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.
